Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

The investment comes as the FDA is pushing drug developers to phase out animal testing in some of the biologic treatments ...

On a positive note, ivonescimab, when used alongside chemotherapy, reduced the risk of disease progression or mortality by 48 ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the pharmaceutical company expands its ...

The French pharmaceutical giant is acquiring a Cambridge biotech and its rare immunology disease which is already approved in ...

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour ...

Curogen, one of South Korea's leading biotechnology companies focused on nanotechnology-based treatments for autoimmune diseases, today announced a series of strategic appointments that strengthen its ...

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...

SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation , and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement ...

SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation , announces three software ecosystem enhancements at ASMS. These developments will present ...